Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-04-15 7:21 pm Sale | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 2,835,875 6.1% | -1,000,100 (-26.07%) | View |
| 2024-04-04 4:39 pm Purchase | 13D | ENLIVEN THERAPEUTICS INC ELVN | ORBIMED ADVISORS LLC | 8,951,463 19.2% | 2,124 (+0.02%) | View |
| 2024-02-16 4:15 pm Sale | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 3,835,975 9.3% | -825,000 (-17.70%) | View |
| 2024-02-14 8:53 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III L.P. | 2,954,902 7.2% | 740,760 (+33.46%) | View |
| 2024-02-14 4:58 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | CITADEL ADVISORS LLC | 2,394,448 5.8% | 95,692 (+4.16%) | View |
| 2024-02-14 4:05 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | COMMODORE CAPITAL LP | 2,901,816 7% | 819,693 (+39.37%) | View |
| 2024-02-14 3:45 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 2,131,369 5.2% | 6,744 (+0.32%) | View |
| 2024-02-14 3:31 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | PFIZER INC PFE | 389,429 0.95% | 389,429 (New Position) | View |
| 2024-02-09 09:03 am Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | FMR LLC | 5,902,265 14.321% | 1,482,684 (+33.55%) | View |
| 2024-02-07 12:16 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | BML Investment Partners L.P. | 50,000 0.1% | 50,000 (New Position) | View |
| 2024-02-02 4:15 pm Sale | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 4,660,975 11.3% | -700,563 (-13.07%) | View |
| 2023-08-28 4:15 pm Sale | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 5,361,538 13% | -436,937 (-7.54%) | View |
| 2023-05-10 09:45 am Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | FMR LLC | 4,419,581 10.749% | 4,419,581 (New Position) | View |
| 2023-04-27 10:00 am Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 2,124,625 5.17% | 2,124,625 (New Position) | View |
| 2023-04-24 4:05 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | COMMODORE CAPITAL LP | 2,082,123 5.1% | 633,483 (+43.73%) | View |
| 2023-03-13 4:01 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | Venrock Healthcare Capital Partners III L.P. | 2,214,142 5.4% | 2,214,142 (New Position) | View |
| 2023-03-06 4:11 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | CITADEL ADVISORS LLC | 2,298,756 5.6% | 2,298,756 (New Position) | View |
| 2023-03-06 4:00 pm Purchase | 13D | ENLIVEN THERAPEUTICS INC ELVN | 5AM Ventures VI L.P. | 5,798,475 14.1% | 5,798,475 (New Position) | View |
| 2023-02-28 4:05 pm Purchase | 13G | ENLIVEN THERAPEUTICS INC ELVN | COMMODORE CAPITAL LP | 1,448,640 3.5% | 1,448,640 (New Position) | View |
| 2023-02-28 4:00 pm Purchase | 13D | ENLIVEN THERAPEUTICS INC ELVN | ORBIMED ADVISORS LLC | 8,949,339 21.8% | 8,949,339 (New Position) | View |